James S. Hardwick

3.8k citations

25 papers · 2.5k indexed · h-index 18

Impact in

Molecular Biology top 5%
- Histone Deacetylase Inhibitors Research
- PI3K/AKT/mTOR signaling in cancer
- Fungal and yeast genetics research
- Protein Kinase Regulation and GTPase Signaling
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
Genetics top 5%

Papers in

Hematology 3
- Acute Myeloid Leukemia Research 2
Molecular Biology 17
- Histone Deacetylase Inhibitors Research 7
- Protein Degradation and Inhibitors 4
- Protein Kinase Regulation and GTPase Signaling 3

Co-authors: Stuart L. Schreiber Bartholomew M. Sefton Randall T. Peterson Bimal N. Desai Jeffrey K. Tong Finny G. Kuruvilla Alykhan F. Shamji Victoria M. Richon
Journals: Proceedings of the National Academy of Sciences (4 papers)Journal of Clinical Oncology (3 papers)Journal of Biological Chemistry (3 papers)Blood (2 papers)Molecular Cancer Therapeutics (1 paper)
Partner nations: United States United Kingdom Japan

In The Last Decade

James S. Hardwick

24 papers receiving 2.5k citations

Peers

Countries citing papers authored by James S. Hardwick

Since Specialization

Citations

This map shows the geographic impact of James S. Hardwick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James S. Hardwick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James S. Hardwick more than expected).

Fields of papers citing papers by James S. Hardwick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James S. Hardwick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James S. Hardwick. The network helps show where James S. Hardwick may publish in the future.

Co-authors

The 25 scholars most cited alongside James S. Hardwick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with James S. Hardwick Line = papers co-authored together James S. Hardwick links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer Oncogene ·Joan Cao, Zhou Zhu, Hui Wang, Timothy C. Nichols, Goldie Y.L. Lui, Shibing Deng, Paul A. Rejto, Todd VanArsdale, James S. Hardwick, Scott L. Weinrich, Ping Wei	2019	30
2	Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Donna M. Weber, Thorsten Graef, Mohamad A. Hussein, Ronald Sobecks, Gary J. Schiller, Lisa Lupinacci, James S. Hardwick, Sundar Jagannath	2012	37
3	Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitroand phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition Leukemia & lymphoma ·Reinhard Dummer, Marc Beyer, Kenneth B. Hymes, Mirjam T. Epping, René Bernards, Matthias Steinhoff, Wolfram Sterry, Helmut Kerl, Karl Heath, А. В. Локтєв, James S. Hardwick, J. Garcia‐Vargas, Katrin Baumann, Syed Rizvi, Stanley R. Frankel, Sean Whittaker, Chalid Assaf	2012	51
4	Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE Journal of Clinical Oncology ·Steven M. Grunberg, Daniel T. T. Chua, N Sarin, José Dinis, Gasanzade Lamiya, Judith A. Boice, James S. Hardwick, Z. Wang, Arlene Taylor, Alexandra D. Carides, Fausto Roila, Jørn Herrstedt	2011	158
5	A 4-Gene Signature Predicts Survival of Patients With Resected Adenocarcinoma of the Esophagus, Junction, and Gastric Cardia Gastroenterology ·Christopher J. Peters, Jonathan Rees, Richard Hardwick, James S. Hardwick, Sarah L. Vowler, Chin‐Ann Johnny Ong, Chunsheng Zhang, Vicki Save, Maria O’Donovan, Doris M. Rassl, Derek Alderson, Carlos Caldas, Rebecca C. Fitzgerald	2010	121
6	Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells Cancer Research ·Sudhir Rao, Jennifer O’Neil, William Edward Byrne, James S. Hardwick, Xudong Dai, Theresa Zhang, Edyta Tyminski, Jing Yuan, Nancy E. Kohl, Victoria M. Richon, Lex H.T. Van der Ploeg, Pamela M. Carroll, Giulio Draetta, A. Thomas Look, Peter R. Strack, Christopher Winter	2009	114
7	Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study Journal of Clinical Oncology ·Evanthia Galanis, Kurt A. Jaeckle, Matthew J. Maurer, Joel M. Reid, Matthew M. Ames, James S. Hardwick, John F. Reilly, Andrey Loboda, Michael Nebozhyn, Valeria R. Fantin, Victoria M. Richon, Bernd W. Scheithauer, Caterina Giannini, Patrick J. Flynn, Dennis F. Moore, James A. Zwiebel, Jan C. Buckner	2009	283
8	Development of vorinostat: Current applications and future perspectives for cancer therapy Cancer Letters ·Victoria M. Richon, J. Garcia‐Vargas, James S. Hardwick	2009	139
9	Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors Cancer Science ·Yutaka Fujiwara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Tetsuya Otsuki, Pepa Cuesta Roldán, Takashi Iwasa, James S. Hardwick, Tomohide Tamura	2009	37
10	Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study Supportive Care in Cancer ·Bernardo L. Rapoport, Karin Jordan, Judith A. Boice, Arlene Taylor, I. M. Belova, James S. Hardwick, Alexandra D. Carides, K Nikas George, Hans‐Joachim Schmoll	2009	185
11	N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology ·E. Galanis, Kurt A. Jaeckle, Matthew J. Maurer, Joel M. Reid, Matthew M. Ames, Caterina Giannini, James S. Hardwick, Dennis F. Moore, James A. Zwiebel, Jan C. Buckner	2007	13
12	Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial. Blood ·Andrey Loboda, Valeria R. Fantin, Carlos E. Bueso‐Ramos, Sophia Randolph, James S. Hardwick, Justin L. Ricker, Victoria M. Richon, Jean‐Pierre J. Issa, Hagop M. Kantarjian, Stanley R. Frankel, Guillermo Garcia‐Manero	2006	2
13	Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling Molecular Cancer Therapeutics ·James S. Hardwick, Yi Yang, Chunsheng Zhang, Bin Shi, Rosemary C. McFall, Elizabeth J. Koury, Susan L. Hill, Hongyue Dai, Robert Wasserman, Robert L. Phillips, Edward J. Weinstein, Nancy E. Kohl, Michael E. Severino, John Lamb, Laura Sepp‐Lorenzino	2005	24
14	Activation of the Lck Tyrosine-protein Kinase by the Binding of the Tip Protein of Herpesvirus Saimiri in the Absence of Regulatory Tyrosine Phosphorylation Journal of Biological Chemistry ·David A. Hartley, Tamara R. Hurley, James S. Hardwick, Troy C. Lund, Peter G. Medveczky, Bartholomew M. Sefton	1999	38
15	Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins Proceedings of the National Academy of Sciences ·James S. Hardwick, Finny G. Kuruvilla, Jeffrey K. Tong, Alykhan F. Shamji, Stuart L. Schreiber	1999	451
16	Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12–rapamycinassociated protein Proceedings of the National Academy of Sciences ·Randall T. Peterson, Bimal N. Desai, James S. Hardwick, Stuart L. Schreiber	1999	427
17	Chemical Genetic and Genomic Approaches Reveal a Role for Copper in Specific Gene Activation Journal of the American Chemical Society ·Brent R. Stockwell, James S. Hardwick, Jeffrey K. Tong, Stuart L. Schreiber	1999	17
18	The transcriptional profile of Saccharomyces cerevisiae exposed to rapamycin mimics the profile induced by amino acid starvation Nature Genetics ·James S. Hardwick, Jeffrey K. Tong, Stuart L. Schreiber	1999	3
19	The Activated Form of the Lck Tyrosine Protein Kinase in Cells Exposed to Hydrogen Peroxide Is Phosphorylated at Both Tyr-394 and Tyr-505 Journal of Biological Chemistry ·James S. Hardwick, Bartholomew M. Sefton	1997	68
20	Stimulation of Phosphorylation of Tyr394 by Hydrogen Peroxide Reactivates Biologically Inactive, Non-membrane-bound Forms of Lck Journal of Biological Chemistry ·覃薇, James S. Hardwick, Kurt E. Amrein, Weiwei Zhu, Bartholomew M. Sefton	1996	24

About James S. Hardwick

James S. Hardwick is a scholar working on Hematology, Molecular Biology, Dermatology, Oncology and Immunology, having authored 25 papers that have together received 2.5k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (7 papers), Nausea and vomiting management (4 papers), Protein Degradation and Inhibitors (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Pathogenesis and Treatment of Hiccups (3 papers), Acute Myeloid Leukemia Research (2 papers), T-cell and Retrovirus Studies (2 papers) and Anesthesia and Pain Management (2 papers). The work is most often cited by research in Molecular Biology (1.7k citations), Genetics (186 citations), Oncology (454 citations), Cancer Research (200 citations) and Immunology (269 citations). James S. Hardwick has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Stuart L. Schreiber, Bartholomew M. Sefton, Randall T. Peterson, Bimal N. Desai, Jeffrey K. Tong, Finny G. Kuruvilla, Alykhan F. Shamji, Victoria M. Richon, J. Garcia‐Vargas and Arlene Taylor. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology, Journal of Biological Chemistry, Blood and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact